UNSPSC 51351707: Trioxifene mesylate

This classification denotes a selective estrogen receptor modulator with the molecular formula C30H31NO3.CH4O3S, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 63ZD22G88L, chemically known as methanone, (3,4-dihydro-2-(4-methoxyphenyl)-1-naphthalenyl)(4-(2-(1-pyrrolidinyl)ethoxy)phenyl)-, methanesulfonate, but more generally known as trioxifene mesylate, which bears US NIH Compound Identifier 50138.

European Medicines Agency schedules trioxifene mesylate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB11317MIG. Most nations, for tariff purposes, schedule trioxifene mesylate under HS 29339990. Trioxifene mesylate bears US NLM identifiers UMLS ID C0146868 and NCI Concept Code C1414. SMILES: COC1CCC(CC1)C2=C(C3CCCCC3CC2)C(=O)C4CCC(CC4)OCCN5CCCC5.CS(=O)(=O)O.

UNSPSC 51351707 Trioxifene mesylate is a Commodity code covering specific pharmaceutical active ingredients and formulations procured by state and local health systems, correctional facilities, and other government-operated medical programs. State and local governments buy this code primarily through cooperative purchasing vehicles and multistate pharmaceutical contracts that consolidate demand across multiple jurisdictions and authorize distribution through established pharmaceutical wholesalers. The actual procurement focuses on manufacturers supplying generic and branded pharmaceutical products with specified National Drug Codes, dosage forms, strengths, and packaging configurations to meet clinical needs across participating state facilities and local government healthcare operations.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and over-the-counter products serving participating state and local government facilities, including Oregon. Proposals are due March 26, 2026, with evaluation weighted heavily on price competitiveness (75 percent), fixed pricing stability (10 percent), and compliance with administrative and technical requirements including EDI capability, administrative fee structure, and supply-chain security certifications. Awarded vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health 110 and 112, Morris & Dickson Co., LLC), comply with current Good Manufacturing Practices and Drug Supply Chain Security Act standards, carry minimum insurance including $5,000,000 commercial general liability and $2,000,000 network security and privacy liability, and accept a 3 percent administrative fee on all purchases. Contract terms are two years for new responders with optional MMCAP extensions, effective July 1, 2026.